Cancer Immunity (15 January 2013) 13: 2
نویسندگان
چکیده
Apoptotic cells are significantly more immunogenic than necrotic cells, even though both forms are identical in antigenic content. When a combination of apoptotic and necrotic cells are used to immunize, the phenotype conferred by apoptotic cells, i.e., high immunogenicity, is dominant. However, necrotic cells are not immunosuppressive or tolerogenic. Apoptotic and necrotic cells are taken up by antigen-presenting cells in an equivalent manner. The priming of naïve T cell response is also equivalent. However, the CD8+ T cells elicited by apoptotic cells expand, accumulate, and express effector function, while those primed by the necrotic cells do not. This dichotomy does not extend to CD4+ cells. Apoptotic and necrotic cells elicit equivalent CD4+ T cell priming, accumulation, and function. The deficit in CD8+ T cell function elicited by necrotic cells can be overcome to varying degrees by anti-CD40 antibody and ligands for TLR4 and TLR9; conversely, the immunogenicity of apoptotic cells can be abrogated by blocking anti-CD154 antibody. Our results indicate that immunization with apoptotic cells leads to engagement of CD40 on antigen-presenting cells; this is essential for their ability to elicit mature functional CD8+ cells. The necrotic cells fail to engage CD40, and this failure is the basis of their lack of immunogenicity. These differences have consequences for the understanding of mechanisms of cross-presentation and for efforts toward immunotherapy of cancers and autoimmune pathologies.
منابع مشابه
Cancer Immunity (15 January 2013) Vol. 13, p. 3
1Department of Oncology, University Hospital Zürich, Zürich, Switzerland 2CT-Atlantic, Schlieren, Switzerland 3Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan-Kettering Cancer Center, New York, NY, USA 4Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan 5Departments of Cancer Vaccine and Immuno-Gene Therapy, Mie University Graduate...
متن کاملCancer Immunity 13:6 (2013)
1Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA 2Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA 3Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA 4Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA *Present address: Eppley Institute for Research in Cancer, Universit...
متن کاملGenetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes
Professional Institutional Original Effective Date: May 13, 2011 Original Effective Date: June 13, 2011 Revision Date(s): January 1, 2012; April 10, 2012; January 15, 2013; March 26, 2013; August 21, 2013; January 1, 2015; March 18, 2015; January 1, 2016; February 3, 2016; May 25, 2016; November 9, 2016 Revision Date(s): January 1, 2012; April 10, 2012; January 15, 2013; March 26, 2013; August ...
متن کاملAdult mesenchymal stem cells and the NO pathways.
listing2011.htm. Accessed January 24, 2013. 13 Gerhardt H, Semb H (2008) Pericytes: Gatekeepers in tumour cell metastasis? J Mol Med (Berl) 86(2):135–144. 14 Klopp AH, et al. (2007) Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 67(24):11687–11695. 15 Krasnov P, et al. (2008) Neuronal nitric oxide synthase contribute...
متن کاملCan immunity to breast cancer eliminate residual micrometastases?
An effective immune response has the potential for breast cancer sterilization with marked reduction in the potential for disease relapse. Adaptive type I immune cells uniquely have the capability of (i) cytotoxic T-cell activation and proliferation until all antigen expressing cells are eradicated, (ii) traversing endothelial barriers to penetrate tumor deposits wherever they occur, and (iii) ...
متن کاملGetting personal with neoantigen-based therapeutic cancer vaccines.
Despite years of preclinical efforts and hundreds of clinical studies, therapeutic cancer vaccines with the routine ability to limit or eliminate tumor growth in humans have been elusive. With advances in genome sequencing, it is now possible to identify a new class of tumor-specific antigens derived from mutated proteins that are present only in the tumor. These "neoantigens" should provide hi...
متن کامل